Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Jul 25, 2022

BUY
$2.27 - $4.86 $15,209 - $32,562
6,700 Added 6.01%
118,200 $327,000
Q2 2021

Jul 26, 2021

BUY
$7.78 - $11.4 $143,930 - $210,900
18,500 Added 19.89%
111,500 $947,000
Q4 2020

Jan 25, 2021

BUY
$3.16 - $7.03 $19,276 - $42,883
6,100 Added 7.02%
93,000 $541,000
Q2 2020

Jul 23, 2020

BUY
$1.58 - $4.63 $11,376 - $33,336
7,200 Added 9.03%
86,900 $401,000
Q4 2019

Jan 24, 2020

BUY
$2.25 - $3.07 $132,525 - $180,823
58,900 Added 283.17%
79,700 $218,000
Q3 2019

Oct 21, 2019

BUY
$2.67 - $3.65 $55,536 - $75,920
20,800 New
20,800 $61,000

Others Institutions Holding AFMD

About Affimed N.V.


  • Ticker AFMD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 149,339,008
  • Market Cap $520M
  • Description
  • Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...
More about AFMD
Track This Portfolio

Track Strs Ohio Portfolio

Follow Strs Ohio and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Strs Ohio, based on Form 13F filings with the SEC.

News

Stay updated on Strs Ohio with notifications on news.